Results 71 to 80 of about 53,349 (300)

An increase in Fusobacterium is associated with the severity of oral mucositis after radiotherapy

Scientific Reports
Radiotherapy is a common treatment for head and neck cancer but often causes oral mucositis, which reduces quality of life. Recent studies suggest that radiotherapy affects the oral microbiota, but whether it contributes to the severity of mucositis has ...
Atsushi Ue, Yukihisa Tamaki, Haruki Usuda, Unta Yamamori, Hiroshi Burioka, Natsuko Nagano, Masafumi Uno, Yoko Sonoyama, Takayuki Okamoto, Koichiro Wada   +9 more
doaj   +1 more source

Patient experiences with oral mucositis caused by chemo-/radiotherapy: a critical qualitative literature review

Nursing Reports, 2014
Mucositis is one of the most common side effects of chemotherapy and radiotherapy. In order to develop an evidence-based clinical practice guideline for the management of tumor therapy-induced-oral mucositis, it was necessary to capture the patients ...
Daniela Zanolin, Christine Widmer, Eva-Maria Panfil   +2 more
doaj   +1 more source

Oral mucositis

National Journal of Maxillofacial Surgery, 2020
Oral mucositis is one of the most common complications of cancer therapy. It is a nonhematologic complication of cytotoxic chemotherapy and radiotherapy and reduces the quality of life. It is estimated that 40% the cases on standard chemotherapy may develop oral mucositis.
Singh, Vibha, Singh, Akhilesh Kumar
openaire   +3 more sources

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study

Integrative Cancer Therapies
Purpose: Radiotherapy-induced oral mucositis is the most common side effect in nasopharyngeal carcinoma (NPC) patients. We aimed to evaluate the efficacy and safety of Rabdosia rubescens drop pills in NPC patients with radiation-induced oral mucositis ...
Lu Li MS, Yecai Huang MD, Jun Yin MD, Peng Xu MS, Mei Lan MD, Churong Li MS, Yunxiang Qi MD, Ke Xu MS, Bosen Li MS, Yukun Luo MS, Qinghua Jiang MS, Shanshan Peng MS, Jinyi Lang MD, Mei Feng MD   +13 more
doaj   +1 more source

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.

PLoS ONE, 2018
BACKGROUND:Radiation-therapy (RT) induces mucositis, a clinically challenging condition with limited prophylactic interventions and no predictive tests.
Mette Marcussen, Mads Sønderkær, Julie Støve Bødker, Maria Andersen, Søren Nielsen, Charles Vesteghem, Ilse Christiansen, Olav Jonas Bergmann, Martin Bøgsted, Karen Dybkær, Mogens Vyberg, Hans Erik Johnsen   +11 more
doaj   +1 more source

The pathogenesis of mucositis : updated perspectives and emerging targets [PDF]

, 2019
Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel
Correa, ME, Correa, M. E., Correa, M.E., Bossi, P., Bossi, P, Bateman, E, Lalla, R.V., Sonis, S, Thorpe, D, Al-Dasooqi, N., Mayo, B., Stringer, A., Al-Dasooqi, N, Sebille, Y. Van, Al-Azri, A., Wardill, H, Al-Azri, A, Bowen, J, Raber-Durlacher, J, ten Bohmer, K., Bateman, E., Bohmer, K. ten, Stringer, A, Thorpe, D., Wardill, H., Cheng, K., Sonis, S., van Sebille, Y, Lalla, RV, Bowen, J., Van Sebille, Y., Mayo, B, Lalla, R. V., Elad, S, Kandwal, A, ten Bohmer, K, Cheng, K, Kandwal, A., Elad, S., Nair, RG, Nair, R. G., Raber-Durlacher, J., Nair, R.G.   +42 more
core   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Mucosal Immunity/Mucosal Vaccine

Nippon Shokuhin Kagaku Kogaku Kaishi, 2009
ヒトや動物には，外敵から身体を守るために免疫系が備わっている．多くのウイルスや病原菌の侵入口である粘膜面には効果的な「粘膜免疫」が存在し，抗原特異的分泌型IgA応答や細胞障害性T細胞（CTL）を誘導する．各粘膜は共通粘膜免疫機構（common mucosal immune system（CMIS））により関連をもち，ある粘膜組織で誘導されたIgA産生細胞やCTLは他の粘膜組織にも帰巣（ホーミング）する．とくに，分泌型IgA産生細胞は，腸管関連リンパ組織（GALT），鼻咽頭関連リンパ組織（NALT）および気管支関連リンパ組織（BALT）などの誘導組織（inductive site）で誘導され，実効組織（effector site）である腸管粘膜固有層，呼吸器粘膜固有層，乳腺，涙腺，唾液腺 ...
openaire   +2 more sources

Peri-implant mucositis

, 2019
Peri-implant mucositis has been defined as a reversible inflammatory reaction in the soft tissues around a functioning implant with no bone loss. This paper reviews the prevalence, etiology, risk indicators, prevention, and treatment of mucositis ...
Froum, Stuart J., de la Torre, Eduardo Gonzalez, Rosen, Paul S.   +2 more
core   +1 more source